文献速递消化道肿瘤与早癌消化内镜

粪便免疫化学试验测定的血红蛋白浓度与晚期结直肠肿瘤长期发生风险的关联

Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia.
PubMed 文献 · Gastroenterology · 2017-07-29

基于荷兰平均风险人群的粪便免疫化学试验(FIT)筛查研究,分析基线FIT阴性(<10 μg Hb/g)者7663例,随访中位4.7年。基线粪便血红蛋白8-10 μg/g者8年晚期结直肠肿瘤累积发生率33%,高于0 μg/g者的5%(P < .001);连续两次8 μg/g者风险为连续两次0 μg/g者的14倍(P < .001)。

要点

  • 基线粪便血红蛋白8-10 μg/g者8年晚期结直肠肿瘤累积发生率为33%,0 μg/g者为5%(P < .001)。
  • 多变量风险比从0-2 μg/g者的1.2升至8-10 μg/g者的8.2(P < .001)。
  • 连续两次粪便血红蛋白8 μg/g者晚期结直肠肿瘤风险为连续两次0 μg/g者的14倍(P < .001)。

核心结论

  • 在FIT结果低于切点值的平均风险人群中,基线粪便血红蛋白8-10 μg/g与0 μg/g相比与晚期结直肠肿瘤风险升高相关。
  • 基线与连续粪便血红蛋白浓度是 incident 晚期结直肠肿瘤的独立预测因素。
  • 该信息可能用于设计人群结直肠癌筛查的个体化策略并减少不必要的重复检测。

研究设计与样本

  • 基于人群的研究,纳入荷兰50-74岁平均风险受试者9561例,2006年11月至2014年12月接受4轮FIT筛查。
  • 分析至少筛查一次且基线FIT阴性(低于10 μg Hb/g粪便切点值)的7663例参与者。
  • 随访中位4.7年(四分位距2.0-6.1年),筛查程序外诊断的结直肠癌从荷兰综合癌症中心数据库识别。
  • 采用Cox比例风险回归分析晚期结直肠肿瘤的风险比,采用逻辑回归计算连续粪便血红蛋白低于切点值后晚期结直肠肿瘤的风险。

主要发现

  • 随访8年后,基线粪便血红蛋白8-10 μg/g者晚期结直肠肿瘤累积发生率为33%,0 μg/g者为5%(P < .001)。
  • 多变量风险比从0-2 μg/g者的1.2升至8-10 μg/g者的8.2(P < .001)。
  • 连续两次粪便血红蛋白8 μg/g者晚期结直肠肿瘤风险为连续两次0 μg/g者的14倍(P < .001)。

关键数值与推荐

  • FIT阳性切点值为10 μg Hb/g粪便。
  • 基线粪便血红蛋白8-10 μg/g者8年晚期结直肠肿瘤累积发生率为33%,0 μg/g者为5%(P < .001)。
  • 多变量风险比:0-2 μg/g者为1.2,8-10 μg/g者为8.2(P < .001)。
  • 连续两次粪便血红蛋白8 μg/g者相较连续两次0 μg/g者的晚期结直肠肿瘤风险比为14(P < .001)。

临床怎么用

  • 原文结论指出基线与连续粪便血红蛋白浓度是 incident 晚期结直肠肿瘤的独立预测因素。
  • 原文结论指出该信息可能用于设计人群结直肠癌筛查的个体化策略并减少不必要的重复检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Colorectal cancer (CRC) screening using quantitative fecal immunochemical tests (FITs) is rapidly gaining ground worldwide. FITs are invariably used in a dichotomous manner using pre-specified cut-off values. To optimize FIT-based screening programs, we investigated the association between fecal hemoglobin (fHb) concentrations below the FIT cut-off value and later development of colorectal advanced neoplasia (AN). METHODS: We analyzed data collected from a population-based study of 9561 average-risk subjects (50-74 years old) in the Netherlands who were offered 4 rounds of FIT screening for CRC from November 2006 through December 2014. We analyzed data from 7663 participants screened at least once and found to have a negative FIT result at baseline (below the cut-off value of 10 μg Hb/ g feces). Participants were followed for a median of 4.7 years (interquartile range, 2.0-6.1 years); CRCs diagnosed outside the screening program were identified from the Dutch Comprehensive Cancer Centre database. Hazard ratios for AN were determined using Cox proportional hazard regression analyses. Logistic regression techniques were used to calculate risks of AN after consecutive fHb concentrations below the cut-off value. RESULTS: After 8 years of follow-up, participants with baseline concentrations of 8-10 μg fHb/g had a higher cumulative incidence of AN (33%) than participants with 0 μg fHb/g (5%) (P < .001). Multi-variate hazard ratios increased from 1.2 for subjects with concentrations of 0-2 μg fHb/g to 8.2 for subjects with concentrations of 8-10 μg fHb/g (P < .001). Participants with 2 consecutive fHb concentrations of 8 μg Hb/g had a 14-fold increase in risk of AN compared with participants with 2 consecutive fHb concentrations of 0 μg Hb/g (P < .001). CONCLUSIONS: In a population-based study of average-risk individuals with a FIT result below the cut-off value, we associated baseline concentrations of 8-10 μg fHb/g with an increased risk of AN compared with baseline concentrations of 0 μg fHb/g. Baseline and consecutive fHb concentrations are independent predictors for incident AN. This information might be used in designing personalized strategies for population-based CRC screening and reduce unnecessary repeat tests. Trialregister.nl no: first round, NTR1096; second round and additional invitees, NTR1512.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Grobbee EJ, Schreuders EH, Hansen BE, et al. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia. Gastroenterology. 2017. PMID: 28760383. doi:10.1053/j.gastro.2017.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。